Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
This study focuses on adults in the United States with schizophrenia who are prescribed xanomeline and trospium chloride XT therapy. It aims to understand patients treatment preferences and satisfaction with this medication combination. The research is observational and tracks real-world experiences rather than testing new treatments. Participants receive xanomeline and trospium chloride therapy according to the product label. The study observes how patients use this treatment and collects information about dosing and any changes over time. Data is gathered at multiple points, including baseline, Month 1, Month 3, and Month 6, to monitor treatment plans and medication adjustments. During the study, participants provide information through questionnaires about their medication preferences and satisfaction. Researchers also collect clinical and demographic data, track treatment plans, dose changes, and reasons for discontinuing therapy. This information helps assess the real-world use and patient experience with XT therapy over approximately six months.
Actively Recruiting
Researchers are conducting a phase 3 clinical trial comparing two treatment combinations for adults with ER-positive, HER2-negative advanced breast cancer who have not received prior systemic anti-cancer treatment for this condition. The study aims to evaluate the effectiveness and safety of palazestrant combined with ribociclib versus letrozole combined with ribociclib. Participants include men and women with locally advanced or metastatic breast cancer not suitable for curative therapy. Participants are randomly assigned to one of two groups. One group receives palazestrant 90 mg once daily, ribociclib 600 mg once daily on days 1-21 of a 28-day cycle, and a placebo matching letrozole daily. The other group receives letrozole 2.5 mg once daily, ribociclib 600 mg once daily on days 1-21 of a 28-day cycle, and a placebo matching palazestrant daily. Treatment cycles repeat every 28 days, and the study includes approximately 1,000 participants worldwide. During the study, participants will be monitored for disease progression and overall survival, with primary measurements taken from the date of randomization until disease progression or death, estimated up to 3.5 years. Safety, drug levels, and patient-reported health outcomes will be assessed regularly. The trial includes long-term follow-up for up to 5.5 years to evaluate overall survival. Participants will have scheduled visits for assessments and monitoring throughout their involvement in the trial.
Actively Recruiting
Researchers are evaluating two different activities to reduce apathy in assisted living residents who have mild to moderate dementia-related memory issues. Apathy can make older adults less interested in doing activities, and this study aims to see if volunteering or joining a current events group can help. This is a supportive care study conducted in multiple assisted living communities in Maryland, with participation being voluntary and not affecting regular care. Participants will be randomly assigned to one of two groups the Volunteering-in-Place VIP Program or a Recreational Activities group focused on current events. Both groups engage in their assigned activity three times a week for about 30 minutes each time, over a total of 6 months. The VIP Program includes personalized volunteer plans, motivational strategies, and adjustments based on participant feedback, while the Recreational Activities group participates in newspaper review sessions as an attention control. Throughout the study, participants will complete questionnaires about their mood, activity level, memory, confidence in volunteering, and feelings of usefulness at the start, after 3 months, and after 6 months. They will also wear a MotionWatch device for 5 weekdays at each time point to measure physical activity. Additional data such as health conditions, medication, and healthcare visits will be collected. The study monitors for minimal risks like privacy concerns, questionnaire fatigue, and mild discomfort from wearing the device. Total participation lasts 6 months.
Actively Recruiting
Researchers are studying a pilot clinical trial to evaluate repetitive transcranial magnetic stimulation rTMS in 34 people with schizophrenia. The trial aims to see if a 5-day, 1 Hertz Hz rTMS treatment targeting the motor cortex can increase brain inhibition, measured by a decrease in the short-interval intracortical inhibition SICI score. The study also explores how rTMS affects the resting functional connectivity of the motor cortex and other brain regions, as well as changes in cognitive performance. Participants with schizophrenia will be randomly assigned to receive either active 1Hz rTMS or a sham placebo version of the treatment. The rTMS involves multiple trains of stimulation each day over five days using either an active or sham device coil. This randomized, double-blind trial is designed to estimate the feasibility and tolerability of the rTMS intervention and to gather preliminary data for future research. During the study, participants will undergo assessments before and after the treatment to measure changes in SICI scores, brain connectivity, and cognitive task performance such as stop signal reaction time and spatial working memory. Additional clinical scales and medication information will be collected to explore relationships with brain inhibition changes. Safety, tolerability, and adherence will be monitored throughout the trial, which is expected to last one week for primary outcome measurement.
Actively Recruiting
Schizophrenia spectrum disorders involve damage to the white matter in the brain, which is important for quick communication between brain regions needed for complex thinking. This damage is linked to difficulties with thinking skills in schizophrenia, especially slower processing speed. The study aims to explore whether training by playing a mock musical instrument can improve white matter structure in people with these disorders. Participants will be randomly assigned to one of two groups. One group will take part in training sessions using the video game Guitar Hero to learn a new skill, while the other group will have observation training. The study will compare changes in white matter microstructure and brain levels of N-acetylaspartate over a 3-week period. Throughout the study, participants will be evaluated using brain scans and other assessments to measure changes in white matter and brain chemistry. The main outcome is the change in white matter microstructure after 3 weeks. Participants will be monitored for safety and adherence during the study, which runs from January 2025 to December 2026, with involvement lasting at least 3 weeks.